Description: RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
Home Page: www.remegen.com
58 Middle Beijing Road
Yantai,
China
Phone:
86 53 56357 3672
Officers
| Name | Title |
|---|---|
| Dr. Jianmin Fang | Co-Founder, CEO, Chief Scientific Officer, Member of Scientific Advisory Board & Exec. Director |
| Dr. Daotian Fu | Pres |
| Mr. Jason Li | CFO & Joint Company Sec. |
| Dr. Marie Zhu | Chief Technical Officer |
| Dr. Ruyi He M.D. | Chief Medical Officer, Head of Clinical Research, Member of Scientific Adv. Board & Exec. Dir. |
| Mr. Jian Lin | Exec. Director |
| Mr. Kaisheng Huang | Chief Quality Officer |
| Ms. Pak Yu Tam A.C.I.S., A.C.S. | Joint Company Sec. |
| Mr. Qingkai Wen | Board Sec. |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 116.1207 |
| Price-to-Book MRQ: | 4.5917 |
| Price-to-Sales TTM: | 26.6666 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2121 |